Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00406887
Other study ID # SJE2079/3-01-PC
Secondary ID
Status Completed
Phase Phase 3
First received November 29, 2006
Last updated November 29, 2006
Start date August 2002
Est. completion date November 2003

Study information

Verified date November 2006
Source Sirion Therapeutics, Inc.
Contact n/a
Is FDA regulated No
Health authority Japan: Institutional Review Board
Study type Interventional

Clinical Trial Summary

The purpose of this phase 3 confirmatory study is to determine if difluprednate ophthalmic emulsion is effective in the treatment of treatment of uveitis.


Description:

The objective of this phase 3 study is to assess the efficacy and safety of 0.05% difluprednate ophthalmic emulsion (DFBA) in patients with endogenous anterior uveitis, in comparison with 0.1% betamethasone sodium phosphate ophthalmic solution (BP).


Recruitment information / eligibility

Status Completed
Enrollment 140
Est. completion date November 2003
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 12 Years and older
Eligibility Inclusion Criteria:

- Patients diagnosed with endogenous anterior uveitis or panuveitis

- Patients with 10 - 49 anterior chamber cells within one field of the anterior chamber as observed by slit lamp microscopy (criterion for rating of signs 2 or 3)

- Patients aged ‰1425 years (on the day of obtaining informed consent) who were able to accurately express their own symptoms

- Patients provided written informed consent prior to initiation of the study

Exclusion Criteria:

- Patients who did not meet all of the above inclusion criteria

- Patients received systemic administration of any corticosteroid or immunosuppressive drug within the past 1 week prior to instillation of the investigational product

- Patients received topical injection of any corticosteroid in eyes prior to instillation of the investigational product (Solution formulation: within the past 1 week, depot: within the past 2 weeks)

- Patients received systemic administration of any non-steroidal anti-inflammatory drug or antiphlogistic enzyme within the past 3 days prior to instillation of the investigational product

- Patients received instillation of any corticosteroid, non-steroidal anti-inflammatory drug or antiphlogistic enzyme within 12 hours prior to instillation of the investigational product

- Patients with glaucoma or ocular hypertension

- Patients with corneal abrasion or ulcer

- Patients with any confirmed or suspected viral, bacterial or fungal keratoconjunctival disease

- Patients with allergy to similar drugs such as other corticosteroids

- Patients requiring use of contact lens during the study period

- Women who are or might be pregnant, or lactating women

- Patients participating in another clinical study within the past 3 months before initiation of the present study

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment


Intervention

Drug:
Difluprednate Ophthalmic Emulsion


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Sirion Therapeutics, Inc.

Outcome

Type Measure Description Time frame Safety issue
Primary The difference from the baseline in anterior chamber cell score on Day 14
Primary was compared between the two groups.
Secondary The differences from the baseline in anterior chamber cell score on Days 3 and 7
Secondary were compared between the two groups.
Secondary The numbers of patients with an anterior chamber cell score of 0 on Days 7 and
Secondary 14 were compared between the two groups.
Secondary The differences from the baseline in total sign and symptom scores on Days 3, 7
Secondary and 14 were compared between the two groups.
Secondary The numbers of patients with an anterior chamber cell score of 1 or less on Days
Secondary 3, 7 and 14 were compared between the two groups.
See also
  Status Clinical Trial Phase
Withdrawn NCT01280669 - Intravitreal Sirolimus as Therapeutic Approach to Uveitis Phase 2
Terminated NCT03656692 - Safety and Effectiveness of Acthar Gel for Inflammation of the Eye's Uvea (Middle Layer) Phase 4
Completed NCT02255032 - Suprachoroidal Injection of Triamcinolone Acetonide in Subjects With Macular Edema Following Non-Infectious Uveitis Phase 2
Recruiting NCT05101928 - Ozurdex Monotherapy Trial Phase 4
Completed NCT00167583 - Interferon-alpha2a Versus Cyclosporin A for Severe Ocular Behcet`s Disease (INCYTOB) Phase 3
Completed NCT02595398 - Suprachoroidal Injection of CLS-TA in Subjects With Macular Edema Associated With Non-infectious Uveitis Phase 3
Recruiting NCT00407316 - Quality of Life and Visual Function in Uveitis Patients Phase 0
Completed NCT02746991 - Safety and Efficacy Study of a FAI Insert in Subjects With Chronic Non-infectious Posterior Uveitis Phase 3
Recruiting NCT06085079 - Ixekizumab for the Management of Refractory Non-Infectious Uveitis: A Proof-of-Concept Study Phase 4
Completed NCT02725177 - Ocular Sarcoidosis Open Label Trial of ACTHAR Gel N/A
Completed NCT00908466 - Sirolimus as Therapeutic Approach to Uveitis Phase 1
Completed NCT00615693 - Safety, Tolerability, and Efficacy of AEB071 in the Treatment of Uveitis Phase 2
Completed NCT00404742 - A Study of LX211 in Clinically Quiescent Non-infectious Intermediate, Anterior and Intermediate, Posterior or Pan-Uveitis Phase 3
Completed NCT00404885 - A Multi-center Study to Assess the Efficacy and Safety of LX211 in Active Non-infectious Anterior Uveitis Phase 3
Completed NCT00404612 - A Study of LX211 in Active Sight Threatening, Non-infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis Phase 3
Completed NCT01789320 - Safety Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle to Treat Uveitis Phase 1/Phase 2
Completed NCT02952001 - MAGNOLIA: Extension Study of Patients With Non-infectious Uveitis Who Participated in CLS1001-301
Completed NCT00407056 - Study of Difluprednate Ophthalmic Emulsion in the Treatment of Severe Uveitis Phase 3
Completed NCT03097315 - Suprachoroidal Injection of CLS-TA in Patients With Non-infectious Uveitis Phase 3